Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer

Figures & data

Figure 1 Overview of the different classes of ovarian cancer treatment.

Abbreviations: ADC, antibody–drug conjugate; ADCC, antibody dependent cellular toxicity; ALK, anaplastic lymphoma kinase; BRAF, v-Raf murine sarcoma viral oncogene homolog B1; Ex, example; mAb, monoclonal antibody; mTOR, mammalian target of rapamycin; SMDC, small molecule drug conjugate; TKI, tyrosine kinase inhibitor.

Table 1 Overview of selected therapies in development for treatment of ovarian cancer

Study drug	Drug type	Trial phase	Patient group	RR, %	PFS (median), months	OS, months	Reference
Gemcitabine	Nucleoside analog	Phase III	Platinum-resistant OC	9.2	3.6	12.7	Mutch et al^Citation20
Gemcitabine	Nucleoside analog	Phase III	Platinum-resistant OC (within 12 months)	29	4.6	11.8	Ferrandina et al^Citation21
Bevacizumab	VEGF antibody	Phase II	Persistent or recurrent OC or primary peritoneal cancer	21	4.7	16.9	Burger et al^Citation29
Bevacizumab (plus standard CT)	VEGF antibody	Phase III	Platinum-resistant OC	30.9	6.7	na	Pujade-Lauraine et al^Citation30
Aflibercept (plus docetaxel)	VEGF decoy receptor	Phase II	Recurrent OC, primary peritoneal cancer, fallopian tube cancer	54	6.2	24.3	Coleman et al^Citation31
Olaparib	PARP inhibitor	Phase II	BRCA mutated platinum-resistant or refractory OC	40	na	na	Fong et al^Citation32
Olaparib (high dose)	PARP inhibitor	Phase II	BRCA mutated recurrent OC	31	8.8	na	Kaye et al^Citation33
Iniparib (plus carboplatin, gemcitabine)	PARP inhibitor	Phase II	Platinum-resistant epithelial OC, primary peritoneal cancer, fallopian tube cancer	31.6	5.9	na	Birrer et al^Citation34
Pemetrexed	Antifolate antineoplastic agent	Phase II	Platinum-resistant OC, primary peritoneal cancer	21	2.9	11.4	Miller et al^Citation35
Pemetrexed	Antifolate antineoplastic agent	Phase II	Platinum-resistant OC, primary peritoneal cancer	9.3	2.8	11.9	Vergote et al^Citation36
Vintafolide	SMDC of folate and DAVLBH	Phase II	Platinum-resistant OC	na	5	na	Naumann 2013^Citation37

Abbreviations: CT, chemotherapy; DAVLBH, desacetylvinblastine hydrazide; na, not available; OC, ovarian cancer; OS, overall survival; PARP, poly (ADP-ribose) polymerase; PFS, progression free survival; RR, response rate; SMDC, small molecule drug conjugate; VEGF, vascular endothelial growth factor.

Figure 2 Chemical construction of vintafolide as a small molecule drug conjugate.

Abbreviation: DAVLBH, desacetylvinblastine hydrazide.

Figure 3 Overview of mechanism of action of vintafolide.

Abbreviations: DAVLBH, desacetylvinblastine hydrazide; FR, folate receptor.

Figure 4 Overview of how etarfolatide can be used to subcategorize patients.

Abbreviation: FR, folate receptor.

MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086

 PubMed Web of Science ®Google Scholar

FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol200826689089618281662

 PubMed Web of Science ®Google Scholar

BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863

 PubMed Web of Science ®Google Scholar

Pujade-LauraineEHilpertFWeberBAURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)J Clin Oncol201230Suppl 15 abstract LBA5002

 Google Scholar

ColemanRLDuskaLRRamirezPTPhase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancerJ Clin Oncol201129Suppl 15 Abstract 5017

 Web of Science ®Google Scholar

FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929

 PubMed Web of Science ®Google Scholar

KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755

 PubMed Web of Science ®Google Scholar

BirrerMJKonstantinopoulosPPensonRTA phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancerJ Clin Oncol201129Suppl Abstract 5005

 Google Scholar

MillerDSBlessingJAKrasnerCNPhase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupJ Clin Oncol200927162686269119332726

 PubMed Web of Science ®Google Scholar

VergoteICalvertHKaniaMKaiserCZimmermannAHSehouliJA randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancerEur J Cancer2009451415142319168349

 PubMed Web of Science ®Google Scholar

NaumannRWColemanRLBurgerRAPRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancerJ Clin Oncol2013In press

 Web of Science ®Google Scholar